Skip to Content

Varubi Dosage

Generic name: ROLAPITANT HYDROCHLORIDE 90mg
Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy

The recommended dosage of VARUBI in adults in combination with a 5-HT3 receptor antagonist and dexamethasone is shown in Table 1. There is no drug interaction between rolapitant and dexamethasone, so no dosage adjustment for dexamethasone is required. Administer a dexamethasone dose of 20 mg on Day 1 [see Clinical Pharmacology (12.3)].

Administer VARUBI prior to the initiation of each chemotherapy cycle, but at no less than 2 week intervals.

Administer VARUBI without regards to meals.

Table 1: Recommended Dosing Regimen
Day 1 Day 2 Day 3 Day 4
Prevention of Nausea and Vomiting Associated with Cisplatin-Based Highly Emetogenic Cancer Chemotherapy
VARUBI 180 mg;
Approximately 1 to 2 hours prior to chemotherapy
None
Dexamethasone 20 mg;
30 min prior to chemotherapy
8 mg twice
daily
8 mg twice
daily
8 mg twice
daily
5-HT3 receptor antagonist See the prescribing information for the co-
administered 5-HT3 receptor antagonist for
appropriate dosing information.
None
Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy and Combinations of Anthracycline and Cyclophosphamide
VARUBI 180 mg;
Approximately 1 to 2 hours prior to
chemotherapy
None
Dexamethasone 20 mg;
30 min prior to chemotherapy
None
5-HT3 receptor
antagonist
See the prescribing information for the co-
administered 5-HT3 receptor antagonist for
appropriate dosing information.
See the prescribing information for the co-
administered 5-HT3 receptor antagonist for
appropriate dosing information.
Hide